← Back to Search

Antibody-drug conjugate

SYD985 for Endometrial Cancer

Phase 2
Waitlist Available
Research Sponsored by Byondis B.V.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new drug for endometrial cancer that has come back or spread. They want to see if it is safe and if it works.

Eligible Conditions
  • Endometrial Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR)
Secondary outcome measures
Incidence of Treatment-Emergent Adverse Events (AEs)
Overall Survival (OS)
Progression-Free Survival (PFS)

Side effects data

From 2014 Phase 4 trial • 32 Patients • NCT01301729
59%
Leukopenia
56%
Neutropenia
34%
Hypoaesthesia
31%
Agranulocytosis
22%
Alopecia
22%
Asthenia
19%
Pyrexia
16%
Nail disorder
16%
Oedema peripheral
16%
Diarrhoea
16%
Hypophagia
13%
Neurotoxicity
13%
Alanine aminotransferase increased
13%
Cough
13%
Vomting
9%
Headache
9%
Musculoskeletal pain
9%
Aspartate aminotransferase increased
9%
Chest discomfort
9%
Rash
9%
Pigmentation disorder
9%
Nausea
9%
Bone marrow failure
9%
Anaemia
6%
Transaminases increased
6%
Insomnia
6%
Constipation
6%
Mouth ulceration
6%
Nasopharyngitis
6%
Paronychia
6%
Flushing
6%
Face oedema
6%
Thrombocytopenia
3%
Infection
3%
Upper respiratory tract infection
3%
Completed suicide
3%
Cataract
100%
80%
60%
40%
20%
0%
Study treatment Arm
Trastuzumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: SYD985Experimental Treatment1 Intervention
SYD985, Intravenous, every 3 weeks (Q3W)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SYD985
2020
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

Byondis B.V.Lead Sponsor
9 Previous Clinical Trials
1,053 Total Patients Enrolled
Maaike Hendriks, MScStudy DirectorByondis B.V., The Netherlands
Norbert KoperStudy DirectorByondis B.V., The Netherlands
1 Previous Clinical Trials
32 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
2020. "SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04205630.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top